We have taken the decision to remove interactions with the HCV primary simeprevir from our website, as this DAA is no longer in use globally for the treatment of HCV. Streamlining our list of primary medications to only include current medications allows us to focus on clinically relevant drug combinations, freeing up more time to add new drugs and to review our database. If there any concerns or queries regarding the removal of simeprevir, we can be contacted at hepgroup@liverpool.ac.uk.
PDFs will be updated in due course.
